Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. chief operating officer Jim Wassil reported equity compensation activity and related tax withholdings. He received 32,045 restricted stock units at a grant price of $0.00 per share, plus an additional 5,102 RSUs at $61.74 per share. He was also granted a stock option for 53,566 shares at a $0.00 exercise price, vesting in monthly installments beginning March 26, 2026.
To cover tax obligations from RSU vesting, shares of common stock were surrendered back to the company: 1,900 shares at $61.74 per share, 898 shares at $61.98 per share, and 1,009 shares at $61.98 per share. After these transactions, he directly owned 175,188 shares of common stock.
Vaxcyte, Inc. entered a new at-the-market stock offering program allowing it to sell up to $500,000,000 of common stock through Leerink Partners as placement agent under an existing shelf registration on Form S-3.
The shares may be sold from time to time on Nasdaq or other permitted markets, with Leerink Partners earning up to 3.00% of gross proceeds. Vaxcyte simultaneously terminated its prior Open Market Sale Agreement with Jefferies, under which it had previously sold approximately $270.3 million of common stock.
Vaxcyte entered into a sales agreement on February 24, 2026 to sell up to $500.0 million of its common stock in an at-the-market offering through Leerink Partners LLC.
The sales agent may sell shares from time to time on mutually agreed terms and will receive a commission of up to 3.0% of gross proceeds. The prospectus cites the last reported sale price of $60.26 per share on February 23, 2026 and states 131,058,858 shares outstanding as of December 31, 2025. The supplement illustrates an example sale of 8,297,378 shares at $60.26 for aggregate gross proceeds of approximately $500.0 million, and shows dilution to new investors of $38.34 per share in that example.
Vaxcyte, Inc. is a clinical-stage vaccine company using its XpressCF cell-free protein synthesis platform to engineer high-fidelity vaccines against serious bacterial diseases. The company focuses on broad-spectrum pneumococcal conjugate vaccines (PCVs) and other novel conjugate and protein vaccines for adults and children.
Its lead candidate, VAX-31, is a 31-valent, carrier-sparing PCV designed to cover about 95% of invasive pneumococcal disease (IPD) in U.S. adults 50+ and about 92% of IPD in children under five. VAX-31 showed strong safety and immunogenicity in a 1,015‑patient Phase 1/2 adult trial versus PCV20, leading to selection of the high dose for a Phase 3 program. The FDA granted breakthrough therapy designation for adult IPD and later expanded it to pneumonia, and Vaxcyte has started three Phase 3 adult studies (OPUS‑1, OPUS‑2 and OPUS‑3).
In pediatrics, VAX-31 is in a large Phase 2 infant dose‑finding study using an optimized higher-dose arm, with enrollment completed and topline data expected in the first half of 2027. VAX-24, a 24‑valent PCV, delivered positive Phase 2 results in infants, showing robust IgG and OPA responses and little evidence of carrier suppression. Additional programs include VAX-A1 for Group A Streptococcus, planned to enter Phase 1 in 2026, and VAX-GI for Shigella, which is paused beyond preclinical work as resources are prioritized toward the PCV franchise.
Vaxcyte, Inc. reported a larger net loss for 2025 while advancing its late-stage pneumococcal vaccine programs and strengthening its balance sheet. The company posted a 2025 net loss of $766.6 million, driven mainly by higher research and development spending of $794.3 million as it moved the VAX-31 adult and infant programs into Phase 3 and Phase 2, respectively, and expanded manufacturing readiness.
Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, not including approximately $600.2 million in net proceeds from a $632.5 million equity offering in February 2026. Vaxcyte highlighted three ongoing Phase 3 adult studies for VAX-31, completed enrollment of a 900-infant Phase 2 study, and plans to start a Phase 1 adult trial for its Group A Strep candidate VAX-A1 in 2026.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting a significant ownership stake in Vaxcyte Inc. common stock. As of 12/31/2025, it reported beneficial ownership of 11,296,333 shares, representing 8.6% of Vaxcyte’s outstanding common stock.
The firm reported sole voting power over 11,064,015 shares and sole dispositive power over 11,296,333 shares, with no shared voting or dispositive power. It states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vaxcyte, and it expressly denies beneficial ownership in a legal-admission sense.
Vaxcyte, Inc. entered into an underwriting agreement to issue and sell 11,000,000 shares of common stock at $50.00 per share to the public, with underwriters purchasing at $47.50 per share. The company granted underwriters a 30-day option to buy up to 1,650,000 additional shares, which they exercised in full. Including this option, Vaxcyte expects net proceeds of approximately $600.2 million after underwriting discounts, commissions and estimated expenses. The offering, made under an effective Form S-3 shelf registration, closed on February 2, 2026 and was led by a syndicate of major investment banks.
Vaxcyte, Inc. is offering 11,000,000 shares of common stock at $50.00 per share, with gross proceeds of $550,000,000 and estimated net proceeds of about $521.9 million after fees and expenses.
The underwriters have a 30-day option to purchase up to 1,650,000 additional shares. As of September 30, 2025, Vaxcyte had 130,029,111 shares outstanding; after this offering, that figure would be 141,029,111 shares on an as-adjusted basis. The company reports preliminary cash, cash equivalents and investments of approximately $2.4 billion as of December 31, 2025, and its capitalization table shows cash, cash equivalents and investments increasing from $2,670.6 million to $3,192.4 million on an as-adjusted basis.
The offering creates immediate dilution for new investors: historical net tangible book value was $21.61 per share, rising to $23.62 per share after the deal, implying dilution of $26.38 per share at the $50.00 offering price. Vaxcyte plans to use the proceeds, together with existing cash, to fund its vaccine development programs and for general corporate purposes, while noting that the funds will not be sufficient to take any product candidate through regulatory approval.
Vaxcyte, Inc. plans a primary offering of common stock and pre-funded warrants, using a Nasdaq-listed common share price as the reference for warrant pricing. The pre-funded warrants carry a $0.001 exercise price and do not expire until fully exercised.
The company is a clinical-stage vaccine developer using a cell-free protein synthesis platform to design complex vaccines for serious bacterial diseases. It preliminarily expects to report about $2.4 billion in cash, cash equivalents and investments as of December 31, 2025 and intends to use new proceeds to strengthen its balance sheet and fund vaccine development programs.
Vaxcyte, Inc. plans a primary offering of common stock and pre-funded warrants, using a Nasdaq-listed common share price as the reference for warrant pricing. The pre-funded warrants carry a $0.001 exercise price and do not expire until fully exercised.
The company is a clinical-stage vaccine developer using a cell-free protein synthesis platform to design complex vaccines for serious bacterial diseases. It preliminarily expects to report about $2.4 billion in cash, cash equivalents and investments as of December 31, 2025 and intends to use new proceeds to strengthen its balance sheet and fund vaccine development programs.
Vaxcyte, Inc. director and CEO Grant Pickering reported an internal share transfer involving company common stock. On January 14, 2026, an entity associated with him transferred 100,000 shares of common stock to an irrevocable trust for estate planning purposes, with a reported price of $0 per share, indicating this was not an open‑market sale. The footnote explains that he no longer has a pecuniary interest in those shares and therefore disclaims beneficial ownership.
Following the transaction, 400,908 common shares are reported as directly owned. In addition, 136,215 common shares are held by a trust for the benefit of his son and another 136,215 common shares are held by a trust for the benefit of his daughter, both reported as indirectly owned through children’s trusts.